453562-01-1

Basic information

• Product Name: Piperazine, 1-methyl-4-[(3-nitrophenyl)sulfonyl]-
• Synonyms: 3-[(4-methylpiperazinyl)sulfonyl]-1-nitrobenzene;1-Methyl-4-[(3-nitrophenyl)sulfonyl]piperazine
• CAS NO: 453562-01-1
• Molecular Formula: C11H15N3O4S
• Molecular Weight: 285.324
• Mol File: 453562-01-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-methyl-4-[(3-nitrophenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-methyl-4-[(3-nitrophenyl)sulfonyl]-(453562-01-1)
• EPA Substance Registry System: Piperazine, 1-methyl-4-[(3-nitrophenyl)sulfonyl]-(453562-01-1)

Safety Data

• Hazardous Substances Data: 453562-01-1(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 127-68-4 sodium 3-nitrobenzenesulfonate 
• 97-08-5 3-nitro-4-chlorosulfonyl chloride 

Downstream Products

• 436095-35-1 3-[(4-methylpiperazinyl)-sulfonyl]-phenylamine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES

The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, dihydroquinoxalinones and dihydropyridopyrazinones of general formula (I), in which A, X, R1, R2, R3, R4, R5, R6, and n have the meanings indicated in the description, intermediate products for producing the compounds according to the invention, pharmaceutical agents containing the compounds according to the invention, and the prophylactic and therapeutic use of said pharmaceutical agents in the case of hyperproliferative diseases, in particular in the case of tumor diseases. The invention further relates to the use of BET protein inhibitors in the case of viral infections, neurodegenerative diseases, inflammatory diseases, and atherosclerotic diseases and in male fertility control.

THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].